X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OQL025 is a first-in disease topical agent to treat moderate to severe acneiform rash in patients receiving EGFR inhibitors. It works by selectively targeting the key pathways that lead to EGFR inhibitor-induced rash.
Lead Product(s): OQL025
Therapeutic Area: Dermatology Product Name: OQL025
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
OQL051 sia first-in-disease, oral, gut-restricted CDK4/6 inhibitor – is designed to prevent the development of CID in patients receiving cytotoxic chemotherapies. The drug works by temporarily arresting the rapidly dividing intestinal mucosal cells in G1 phase.
Lead Product(s): OQL051
Therapeutic Area: Gastroenterology Product Name: OQL051
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
OQL036 is a novel topical agent that locally alleviates the toxicities induced by capecitabine metabolites, and reduces the inflammation associated with capecitabine-induced hand-foot syndrome (HFS).
Lead Product(s): OQL036
Therapeutic Area: Dermatology Product Name: OQL036
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
OQL011 is a proprietary ointment that locally activates VEGF downstream signaling pathways to treat HFSR in cancer patients. OQL011 improves or restores VEGF signaling in cell viability and functionality to alleviate HFSR symptoms.
Lead Product(s): OQL011
Therapeutic Area: Dermatology Product Name: OQL011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
NOVA-II trial is evaluating OQL011, a topical ointment for the management of Hand-Foot Skin Reaction (HFSR) in cancer patients receiving vascular endothelial growth factor receptor inhibitor(s) (VEGFRi) as part of their treatment.
Lead Product(s): OQL011
Therapeutic Area: Dermatology Product Name: OQL011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
Preclinical data from in vitro and in vivo experiments showing that OQL051, a gut-restricted CDK4/6 inhibitor, had significant efficacy in protecting gastrointestinal tissues from damage and decreasing diarrhea caused by chemotherapy for prevention of CID.
Lead Product(s): OQL051
Therapeutic Area: Gastroenterology Product Name: OQL051
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
OnQuality will present an update on its NOVA-II Phase 2 clinical trial investigating OQL011, a proprietary ointment designed to treat HFSR, including findings from Part 1 and plans for Part 2 of the study.
Lead Product(s): OQL011
Therapeutic Area: Dermatology Product Name: OQL011
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
Part 1 of Phase 2 NOVA-II clinical trial evaluating OQL011 met the company's primary safety and efficacy expectations, after the favorable results OnQuality is all set to begin Part 2 of NOVA-II in Q1 2022.
Lead Product(s): OQL011
Therapeutic Area: Dermatology Product Name: OQL011
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2022
Details:
Proceeds from the financing will support the Phase II clinical trial of the company's leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
Lead Product(s): OQL011
Therapeutic Area: Dermatology Product Name: OQL011
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Shiyu Capital
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 31, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
